Long-Term Effects of Atidarsagene Autotemcel for Metachromatic Leukodystrophy

Among patients with presymptomatic late-infantile or early-juvenile MLD and those with early-symptomatic early-juvenile MLD, the risk of severe motor impairment or death was significantly lower among those who received treatment with arsa-cel than in a natural history cohort that did not receive treatment. (Funded by Orchard Therapeutics and others; ClinicalTrials.gov numbers, NCT01560182 and NCT03392987.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-04-23
DOI
https://doi.org/10.1056/nejmoa2405727
Citations
14
Primary Topic
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
Type
article
Field-Weighted Citation Impact
10.37

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-Term Effects of Atidarsagene Autotemcel for Metachromatic Leukodystrophy

Francesca Ferrua, Massimo Filippi, Mara Sangalli, Cristina Baldoli et al.
14 citations
New England Journal of Medicine
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
10.37
article

Long-Term Effects of Atidarsagene Autotemcel for Metachromatic Leukodystrophy

Francesca Ferrua, Massimo Filippi, Mara Sangalli, Cristina Baldoli, Fabio Ciceri, Matías Soncini, Valeria Calbi, Francesca Ciotti, Maria Pia Cicalese, Marcella Facchini, Maddalena Fraschini, Francesco Morena, Salvatore Marco Recupero, Elena Sophia Fratini, Andrew Shenker, Fabiola De Mattia, Stefano Scarparo, Maria Grazia Natali Sora, Alessandro Aiuti, Stefano Zancan, Maddalena Migliavacca, Alberto A. Zambon, Francesca Tucci, Alan E. Richardson, Ambra Corti, Marina Sarzana, Paolo Silvani, Eugenio Montini, Vera Gallo, Simona Miglietta, Giulia Consiglieri, Maria Rosa Calvi, Luigi Naldini, Sean Moro, Federica Barzaghi, Maria Ester Bernardo, Alessia Ippolito, Francesca Fumagalli, Muska Yarzi, Laura Campbell, Sabata Martino, Alessandra Clerici, Sara M. Locatelli, Jean Brooks, Nicholas D. Gollop, Philippa Nutkins, Clelia Pierini, Federica Miotto, Angélica Córdoba-Claros, Jeff Abate, Mattia Calissano
article en
14 citations

Abstract

Among patients with presymptomatic late-infantile or early-juvenile MLD and those with early-symptomatic early-juvenile MLD, the risk of severe motor impairment or death was significantly lower among those who received treatment with arsa-cel than in a natural history cohort that did not receive treatment. (Funded by Orchard Therapeutics and others; ClinicalTrials.gov numbers, NCT01560182 and NCT03392987.).

New England Journal of MedicineVol. 392(16)
Vita-Salute San Raffaele University (IT), University of Perugia (IT), Mylan (South Africa) (ZA), The San Raffaele Telethon Institute for Gene Therapy (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione Telethon (IT), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
GlaxoSmithKline, Fondazione Telethon
Zero hunger
Openalex Percentile: Top 1%
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
10.37
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.